Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genital Herpes Simplex Virus (HSV) Infection During Pregnancy - Recommendations of the Working Group on Obstetrics and Prenatal Medicine (AGG - Section on Maternal Disorders).

Geburtshilfe und Frauenheilkunde·2026
Same author

Economic value of anti-CD20 therapies in multiple sclerosis: a systematic review of cost-effectiveness studies.

Therapeutic advances in neurological disorders·2026
Same author

Virus-Specific T Cells and Response to Checkpoint Inhibitors in Progressive Multifocal Leukoencephalopathy.

JAMA neurology·2026
Same author

A multicenter, prospective cohort study on the anti-SARS-CoV-2 vaccination response in patients with multiple sclerosis in Germany.

Frontiers in neurology·2025
Same author

Guidelines for diagnosis and treatment in neurology - Lyme neuroborreliosis.

German medical science : GMS e-journal·2025
Same author

Cutaneous Lyme borreliosis: Guideline of the German Dermatology Society.

German medical science : GMS e-journal·2025

Related Experiment Video

Updated: Mar 7, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.8K

The MRZ reaction in primary progressive multiple sclerosis.

Tilman Hottenrott1, Rick Dersch2, Benjamin Berger2

  • 1Department of Neurology and Neurophysiology, University Medical Center Freiburg, Breisacher Strasse 64, 79106, Freiburg, Germany. tilman.hottenrott@uniklinik-freiburg.de.

Fluids and Barriers of the CNS
|February 8, 2017
PubMed
Summary

The MRZ reaction (MRZR) is as common in primary-progressive multiple sclerosis (PPMS) as in relapsing-remitting multiple sclerosis (RRMS). This diagnostic marker is significantly less frequent in other inflammatory neurological diseases (OIND).

Keywords:
Intrathecal polyspecific antiviral immune responseMRZ reactionMRZROCBOligoclonal bandsPPMSPrimary progressive multiple sclerosis

More Related Videos

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.1K
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

10.0K

Related Experiment Videos

Last Updated: Mar 7, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.8K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.1K
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

10.0K

Area of Science:

  • Neurology
  • Immunology
  • Diagnostic Markers

Background:

  • The MRZ reaction (MRZR), a panel of antibody indices against measles, rubella, and varicella zoster virus, is frequently positive in relapsing-remitting multiple sclerosis (RRMS).
  • Its diagnostic utility in primary-progressive multiple sclerosis (PPMS) and other inflammatory neurological diseases (OIND) remains less understood.

Purpose of the Study:

  • To determine the prevalence of the MRZ reaction (MRZR) in patients with primary-progressive multiple sclerosis (PPMS).
  • To compare MRZR positivity rates between PPMS, relapsing-remitting multiple sclerosis (RRMS), and other inflammatory neurological diseases (OIND).

Main Methods:

  • MRZR was assessed in 103 PPMS patients, 100 RRMS patients, and 48 OIND patients.
  • Two stringency levels were used: MRZR-1 (≥1 positive antibody index) and MRZR-2 (≥2 positive antibody indices).

Main Results:

  • MRZR-1 positivity was 83.5% in PPMS and 67.8% in RRMS (p < 0.05).
  • MRZR-2 positivity was 54.4% in PPMS and 43.0% in RRMS (not significant).
  • OIND patients showed significantly lower MRZR positivity rates (MRZR-1: 22.9%, MRZR-2: 8.3%; p < 0.0001).

Conclusions:

  • The MRZ reaction (MRZR) is highly prevalent in both PPMS and RRMS patients.
  • MRZR positivity is significantly lower in OIND, supporting its role in differentiating MS subtypes from other neurological inflammatory conditions.